Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Research Center

Neither a doctor nor a teaching hospital

Research payments

$2,422,185

366 payments

Through program year 2025, Advanced Research Center is reported as receiving $2,422,185 in research payments, across 366 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$691,552	37
2024	Research	$540,814	51
2023	Research	$279,166	116
2022	Research	$91,146	83
2021	Research	$6,506	27
2020	Research	$5,299	5
2019	Research	$807,702	47

Breakdown

Who paid Research payments · program years 2019–2025

Boehringer Ingelheim Pharmaceuticals, Inc. $541,867 10 payments
E.R. Squibb & Sons, L.L.C. $474,550 21 payments
Biogen, Inc. $444,863 2 payments
Allergan Inc. $365,626 41 payments
Corium, Inc. $210,843 19 payments
Novo Nordisk AS $154,706 43 payments
Collegium Pharmaceutical, Inc. $59,280 3 payments
Ironshore Pharmaceuticals Inc. $45,866 1 payment
AbbVie, Inc. $40,642 21 payments
Sumitomo Pharma America, Inc. $26,698 113 payments

Studies the money was for Research payments · program years 2019–2025

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease $444,863 2 payments
Proof of concept and DRF in BPD $173,183 2 payments
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia $166,533 3 payments
Nn6535-4725 $154,706 43 payments
A phase III trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-3) $152,634 2 payments
A Double Blind, Placebo- and Active Controlled Evaluation of the Safety and Efficacy of Levomilnacipran Er in Adolescent Patients With Major Depressive Disorder $140,073 9 payments
Connex 3 $138,860 1 payment
An Efficacy and Safety Study w/ Azstarys in Children With ADHD $109,617 5 payments
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $78,339 2 payments
Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Or Most Recent Episode Is Manic $66,810 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.